CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 682 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Clopidogrel 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00799396
NCT00799396Phase 4Completed
CompareCT.gov

Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)

University of Maryland, Baltimore·interventional·Posted Nov 27, 2008·Updated Feb 24, 2022

In Brief

A Phase 4 clinical trial evaluating Clopidogrel and Aspirin for Platelet Aggregation Inhibitors and Coronary Heart Disease. Completed, enrolled 682 participants across 1 site.

Detailed Summary

One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications. The variance in treatment response may be linked to genetics. This study will examine the effects of aspirin and clopidogrel in a population whose genes are well known in order to determine the role that genes play in treatment responses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlatelet Aggregation Inhibitors, Coronary Heart Disease
CountriesUnited States
CollaboratorsNational Institute of General Medical Sciences (NIGMS), National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 27, 2008
Enrollment StartJul 1, 2006
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 17.6 years ago

Interventions

Clopidogreldrug

300 mg on first day, then 75 mg per day for the next 6 days

Aspirindrug

Single dose of 324 mg on the last day of clopidogrel treatment